Europe Ovarian Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

[Report Description]

The major factors that drive the European ovarian cancer diagnostics and therapeutics market are increasing geriatric women population, rise in ovarian cancer cases, and greater use of combination therapies for the treatment of ovarian cancer. The incidences of ovarian cancer are high in women, who are aged between 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. As per Cancer Research UK, ovarian cancer is the fifth most common cancer in Europe for females. Moreover, as per Globocan estimates, Europe recorded 67,771 new ovarian cancer cases in 2018, with 44,576 deaths. With the rising burden of cancer, there is a rising need for effective treatment. Hence, owing to these factors, the market is expected to witness significant growth over the forecast period.

Key Market Trends

Chemotherapy is Expected to Hold Largest Share of the Europe Ovarian Cancer Diagnostics and Therapeutics Market

Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain area, but chemotherapy works throughout the whole body. This means chemotherapy can kill and damage cancer cells that have spread to other parts of the body, which are far away from the original tumor. Chemotherapy-based drugs have been the choice of treatment over decades and have been the main treatment option for several types of cancer. Hence, owing to the above-mentioned factors, along with the rising burden of ovarian cancer, the market for chemotherapy is expected to grow during the forecast period.

Competitive Landscape

The European ovarian cancer diagnostics and therapeutics market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers and acquisitions, new product launches, and partnerships that help them in strengthening their market position. For instance, in 2019, Bristol-Myers Squibb Company has acquired Celgene, which has widened the company’s pipeline in oncology, hematology, immunology, and cardiovascular disease.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support